A
Anthony Williams
Researcher at University of Miami
Publications - 35
Citations - 2076
Anthony Williams is an academic researcher from University of Miami. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 17, co-authored 33 publications receiving 1859 citations. Previous affiliations of Anthony Williams include University of Southern California & University of Chicago.
Papers
More filters
Journal ArticleDOI
Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells
Henry K. Lin,Siyang Zheng,Anthony Williams,Marija Balic,Susan Groshen,Howard I. Scher,Martin Fleisher,Walter M. Stadler,Ram H. Datar,Yu-Chong Tai,Richard J. Cote +10 more
TL;DR: A novel parylene membrane filter-based portable microdevice for size-based isolation with high recovery rate and direct on-chip characterization of captured CTC from human peripheral blood has the potential to enable routine CTC analysis in the clinical setting for the effective management of cancer patients.
Journal ArticleDOI
3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood
TL;DR: The paper presents and validates this new 3D microfiltration concept for circulation tumor cell enrichment application and provides a highly valuable tool for assessing and characterizing viable enriched circulating tumor cells in both research and clinical settings.
Journal ArticleDOI
CORRIGENDUM: Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells.
Ming Da Zhou,Sijie Hao,Anthony Williams,Ramdane Harouaka,Brett Schrand,Siddarth Rawal,Zheng Ao,Randall Brenneman,Eli Gilboa,Bo Lu,Shuwen Wang,Jiyue Zhu,Ram H. Datar,Richard J. Cote,Yu-Chong Tai,Siyang Zheng +15 more
TL;DR: In this paper, a separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells was proposed for transplanting cancer cells.
Journal ArticleDOI
Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer
Zheng Ao,Sanket Shah,Leah Machlin,Ritesh Parajuli,Philip Miller,Siddarth Rawal,Anthony Williams,Richard J. Cote,Marc E. Lippman,Ram H. Datar,Dorraya El-Ashry +10 more
TL;DR: The presence of cCAFs was associated with clinical metastasis, suggesting that cCAF may complement CTC as a clinically relevant biomarker in metastatic breast cancer.
Journal ArticleDOI
Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
Steven J. O'Day,Rene Gonzalez,David H. Lawson,R. W. Weber,Laura F. Hutchins,Clay M. Anderson,Jonathan Haddad,S. Kong,Anthony Williams,Eric W. Jacobson +9 more
TL;DR: E + P resulted in a statistically significant doubling of median PFS, with an acceptable toxicity profile and encouraging OS, in patients with stage IV metastatic melanoma.